Neurotech International @NeurotechInt

Thank you to everyone who attended today’s presentation by Managing Director and CEO Dr Anthony Filippis at the 2026 Gold Coast Investment Showcase. Anthony provided an update on Neurotech’s progress, including the development of NTI164 and the Company’s upcoming clinical and corporate milestones. For those who were unable to attend, we will share a replay of the presentation as soon as it becomes available. If you’re attending the conference, we invite you to stop by the Neurotech booth and meet with Anthony and the Neurotech team to learn more about the Company and our development programs. We look forward to seeing you there. $NTI

keyboard_arrow_left Previous keyboard_arrow_right Next

REMINDER | We’re looking forward to attending the Gold Coast Investment Showcase on 11 and 12 June 2026 at the JW Marriott Gold Coast Resort & Spa, Queensland. Managing Director and CEO Dr Anthony Filippis will present on Thursday, 11 June at 12:00 pm, providing an update on Neurotech’s recent progress and upcoming milestones. For conference information and registration: goldcoastinvestmentshowcase.com.au #NTI #Neurotech @VEvents_RIU #Biotech

Thank you to everyone who joined us at Neurotech’s Investor & Advocacy Day yesterday. It was a special afternoon bringing together families, medical professionals, advocates and the Neurotech team to share experiences, discuss NTI164 and hear firsthand about the impact the treatment is having on patients and their families. We’re grateful to the families who shared their stories and to everyone who took the time to be part of the day. $NTI

keyboard_arrow_left Previous keyboard_arrow_right Next

We’re looking forward to attending the Gold Coast Investment Showcase on 11 and 12 June 2026 at the JW Marriott Gold Coast Resort & Spa, Queensland. Managing Director and CEO Dr Anthony Filippis will present on Thursday, 11 June at 12:00 pm, providing an update on Neurotech’s recent progress and upcoming milestones. For conference information and registration: goldcoastinvestmentshowcase.com.au #NTI #Neurotech @VEvents_RIU #Biotech

REMINDER | We’re hosting our Neurotech Investor & Advocacy Day on 21 May 2026. Join us for a meaningful gathering of families, professionals and community advocates to hear from the team behind Neurotech, alongside medical professionals and families sharing insights into NTI164 and the impact the treatment is having on patients and their lives. The event is an opportunity to connect, learn and support the children and families who need it most. Canapés and light refreshments will be served following the presentations. To reserve your place, RSVP $NTI by 14 May 2026 to [email protected]. #Neurotech #Investors #Biotech

We’re hosting our @NeurotechInt Investor & Advocacy Day on 21 May 2026. Join us for a meaningful gathering of families, professionals and community advocates to hear from the team behind Neurotech, alongside medical professionals and families sharing insights into NTI164 and the impact the treatment is having on patients and their lives. The event is an opportunity to connect, learn and support the children and families who need it most. Canapés and light refreshments will be served following the presentations. To reserve your place, RSVP by 14 May 2026 to [email protected]. $NTI #Neurotech #Investors #Biotech

We’ll be presenting at the 1st Australian Microcap Investment Conference in Sydney on Monday, 11 May. MD and CEO Dr Anthony Filippis will present at 3:00 pm, providing an overview of Neurotech’s strategy, clinical progress and growth outlook. Fullerton Hotel, Sydney Monday, 11 May 2026 To register: microcapconferences.com/event/sydney/r… #AusMicrocap #Biotech #ASX $NTI

Watch Managing Director and CEO Dr Anthony Filippis provide a brief update from the Ignite Summit in Hong Kong, outlining Neurotech’s recent clinical and corporate milestones and the next stage of delivery. $NTI #ASX #SmallCaps #CapitalMarkets #Mining #MarketOpen #IgniteSummit #IgnitePartners

Our Quarterly Activities Report for the period ending 31 March 2026 has been released. View the full $NTI report: api.investi.com.au/api/announceme…

Our CEO & Managing Director, Dr Anthony Filippis, presented at the Ignite Investment Summit Hong Kong last week, where he discussed Neurotech’s progress advancing NTI164. A replay of the presentation is now available: youtube.com/watch?v=xOPESl… $NTI #Neurotech #Autism #ASD #Biotech #Ignite #Conference

Biocurious: Stay tuned as drug developers get to the pointy end of their efforts | Media coverage by @StockheadAU stockhead.com.au/health/biocuri… $NTI #Neurotech #Autism #ASD #Biotech

We’re proud to share that our U.S. Medical Advisor, Dr Bonni Goldstein, MD has been appointed to the newly formed National Compassionate Care Council. The Council is focused on U.S. cannabis and healthcare policy reform and will be responsible for activities spanning informing policy, clinical practice, research and patient access. Its mandate includes providing clinical and scientific guidance to inform the safe and appropriate use of medical cannabis, developing frameworks to support cannabis as a recognised therapeutic option, and promoting the use of real-world data and clinical evidence to guide dosing, safety, and efficacy considerations. We look forward to the meaningful contributions Dr Goldstein will make in advancing a more accessible, equitable, and evidence-based framework for cannabinoid-based therapies. Read the full Media Release here: lnkd.in/gfgEGugR #Neurotech #ASX $NTI #DrBonniGoldstein #CannabisMedicine #HealthcarePolicy #ClinicalEvidence #PatientAccess #CannabinoidTherapies

We’ve wrapped up our time at the Ignite Investment Summit Hong Kong, where our CEO & Managing Director, Dr Anthony Filippis, presented Neurotech’s progress advancing NTI164. The Summit provided a great opportunity to meet with investors and discuss NTI164, our novel broad-spectrum oral cannabinoid therapy being developed for childhood neurological and neurodevelopmental disorders, including Autism Spectrum Disorder, Rett Syndrome and PANDAS/PANS. We thank Ignite Partners, the organisers, and everyone who took the time to meet with us during the conference. $NTI

keyboard_arrow_left Previous keyboard_arrow_right Next

REMINDER | Our CEO & MD, Dr Anthony Filippis, is attending the Ignite Summit HK in Hong Kong, hosted at the Grand Hyatt, Wan Chai. Dr Filippis will be presenting on Day 1, Wednesday 15 April at 3:10pm, sharing an update on Neurotech’s clinical development programs and the advancement of NTI164 in paediatric neurological disorders. If you are attending the Summit, we welcome the opportunity to connect. #IgniteInvestmentSummit #HongKong #InvestorMeetings #LifeSciencesInvestment #Neurotech #ASX #NTI #IgniteSummitHK #Biotechnology #PaediatricNeurology

We’re presenting at the Ignite Investment Summit in Hong Kong this week, with our CEO & MD, Dr Anthony Filippis, representing Neurotech. Anthony will discuss NTI164, our broad-spectrum oral cannabinoid therapy, and its development as a novel therapy for childhood neurological and neurodevelopmental disorders. He will deliver a group presentation at 3:10pm HKT / 5:10pm AEST on Wednesday 15 April 2026, alongside a series of investor meetings across the Summit. If you are attending, we look forward to connecting. $NTI Presentation: api.investi.com.au/api/announceme…

Neurotech opens first site for phase III autism trial | $NTI Media coverage The Australian. theaustralian.com.au/business/stock… #Neurotech #NTI #Autism #ASD #Biotech